雷珠单抗联合激光手术治疗视网膜分支静脉阻塞继发黄斑水肿疗效观察  

Effect of ranibizumab combined with laser surgery in the treatment of macular edema secondary to retinal branch vein occlusion

作　　者：简飞龙 廖锐[1] 段娜[1] JIAN Fei-long;LIAO Rui;DUAN Na(Department of Ophthalmology,Huizhou Third People's Hospital,Huizhou 516000,Guangdong,CHINA)

机构地区：[1]惠州市第三人民医院眼科,广东惠州516000

出　　处：《海南医学》2022年第17期2226-2229,共4页Hainan Medical Journal

摘　　要：目的观察雷珠单抗联合激光手术治疗视网膜分支静脉阻塞继发黄斑水肿(BRVO-ME)的疗效及其安全性。方法选择2020年7月至2021年1月惠州市第三人民医院眼科接诊的80例BRVO-ME患者作为研究对象,按照随机数表法分为观察组和对照组各40例。对照组患者给予激光手术治疗,观察组患者在对照组基础上联合雷珠单抗治疗。比较两组患者治疗6个月后的临床疗效,治疗前、治疗6个月后的最佳矫正视力(BCVA)、平均光感器层厚度(PLT)、黄斑区视网膜厚度(CMT)、眼压的变化以及并发症发生情况。结果治疗后,观察组患者的临床疗效总有效率为92.50%,明显高于对照组的75.00%,差异有统计学意义(P<0.05);治疗后,观察组患者的BCVA、PLT分别为(0.84±0.11)logMAR、(77.52±6.80)μm,均明显高于对照组的(0.75±0.09)logMAR、(72.36±6.18)μm,CMT、眼压分别为(247.20±36.38)μm、(10.56±1.58)mmHg,明显低于对照组的(329.51±41.52)μm、(13.02±1.33)mmHg,差异均有统计学意义(P<0.05);观察组和对照组患者并发症总发生率分别为5.00%和7.50%,差异无统计学意义(P>0.05)。结论雷珠单抗联合激光手术治疗BRVO-ME可有效改善患者的BCVA、PLT、CMT,促进病情恢复,临床应用效果显著,且安全性较高。Objective To observe the efficacy and safety of ranibizumab combined with laser surgery in the treatment of macular edema secondary to branch retinal vein occlusion(BRVO-ME).Methods Eighty patients with BRVO-ME treated in Department of Ophthalmology,Huizhou Third People's Hospital from July 2020 to January 2021 were selected as the research objects.According to random number table,they were randomly divided into an observation group and a control group,with 40 patients in each group.The patients in the control group were treated with laser surgery,and the patients in the observation group were treated with ranibizumab on the basis of the control group.The clinical efficacy at 6 months after treatment,and the changes of best corrected visual acuity(BCVA),mean photoreceptor layer thickness(PLT),and macular retinal thickness(CMT),and intraocular pressure before and at 6 months after treatment,and the incidence of complications in the two groups were compared.Results After treatment,the total effective rate in the observation group was 92.50%,which was significantly higher than 75.00%in the control group(P<0.05);after treatment,BCVA and PLT in the observation group were(0.84±0.11)logMAR and(77.52±6.80)μm,which were significantly higher than(0.75±0.09)logMAR and(72.36±6.18)μm of the control group,and the CMT and intraocular pressure were(247.20±36.38)μm and(10.56±1.58)mmHg,which were significantly lower than(329.51±41.52)μm and(13.02±1.33)mmHg of the control group,with statistically significant difference(P<0.05).The total incidence of complications in the observation group and the control group was 5.00%and 7.50%,respectively,and the difference was not statistically significant(P>0.05).Conclusion Ranibizumab combined with laser surgery in treatment of BRVO-ME can effectively improve BCVA,PLT,and CMT of patients,and promote the recovery of the disease,with significant clinical effect and high safety.

关 键 词：视网膜分支静脉阻塞 黄斑水肿 最佳矫正视力 平均光感器层厚度 黄斑区视网膜厚度 疗效 安全性 

分 类 号：R774.1[医药卫生—眼科]